Managing constipation on Mounjaro: what actually helps

Why Mounjaro causes constipation in the first place

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, to reduce appetite and slow the rate at which your stomach empties. That last part is a feature of the medicine, not a flaw, it contributes to the feeling of fullness that makes the treatment work. But slower gastric emptying also means slower movement further down the gut, and that is what tips some people into constipation during Mounjaro treatment.

It is most likely to appear in the first four weeks of treatment, or in the days following a dose increase, when the effect on gut motility is at its strongest. The NHS tirzepatide information page lists constipation alongside nausea and diarrhoea as commonly reported gastrointestinal effects. For most people it is mild and temporary, and if you want a thorough explanation of why Mounjaro causes constipation and how the gut changes throughout treatment, that is covered in full detail on its own page. A smaller number find it persists, and that group tends to need a more structured approach rather than waiting it out.

If you have experienced the opposite problem, diarrhoea during Mounjaro treatment is covered separately, the management strategies differ considerably, and conflating the two can make things worse.

The factors that influence how bad it gets, and what you can do about them

Three things have the biggest bearing on whether constipation on tirzepatide stays mild or becomes genuinely uncomfortable: hydration, fibre intake, and physical activity. All three tend to drop when appetite is suppressed. When you eat less, fibre intake often falls with it. When you feel nauseated or sluggish, drinking enough water can slip too. And if energy levels dip early in treatment, movement reduces. The gut notices all of it.

A practical check worth building into your morning: before anything else, note whether you have drunk enough water the previous day and whether yesterday's meals included any vegetables, pulses or wholegrains. Takes less than a minute, and consistently flagging the pattern is often what breaks it. Gradually increasing fibre (rather than adding a lot at once, which can cause bloating) is the approach the NHS healthy weight guidance supports alongside weight management treatment.

Over-the-counter osmotic laxatives, such as macrogol, are generally considered appropriate for short-term use, but you should check with your prescriber or pharmacist before starting anything regularly. Your prescriber can also advise whether the timing of your weekly injection relative to your gut symptoms is relevant, a question our team at the nume clinical team fields regularly. The fuller picture of what helps, including what to avoid, is covered in detail on the how to stop constipation on Mounjaro page.

When constipation on tirzepatide needs medical attention

Most constipation during Mounjaro treatment is uncomfortable but not dangerous. There are specific situations, though, where it stops being a side-effect management question and becomes a clinical one.

Get medical help promptly if you experience severe abdominal pain, particularly pain that radiates towards your back, with or without vomiting. This symptom pattern can indicate acute pancreatitis, which the MHRA identified in its January 2026 Drug Safety Update as an infrequent but serious risk with GLP-1 medicines. The symptom is not typical constipation discomfort, it tends to be persistent, more intense, and does not resolve with laxatives.

Also seek advice if you have not had a bowel movement for more than a week, if you notice blood in your stool, or if constipation is accompanied by significant bloating, vomiting, or complete inability to pass wind. These warrant a call to your GP or, if the pain is severe, NHS 111 or A&E.

Outside of those situations, constipation that is simply persistent (present for two or three weeks without improvement) is worth raising at your next prescriber review rather than continuing to manage alone. The full side-effect picture for Mounjaro explains how the clinical team approaches ongoing symptoms, and you can always reach the nume team through our support line if something feels off between reviews.

When to involve your prescriber in the decision

Constipation during tirzepatide treatment sits in an interesting middle ground: it is common enough that many people assume it just has to be tolerated, but manageable enough that most people do not need to. The decision about whether to act (and how) depends on severity, how long it has lasted, and what else is happening with your treatment.

Mild constipation in the first couple of weeks, settling with hydration and fibre adjustments, usually does not need a prescriber call. Constipation that is significantly affecting your quality of life, that recurs with every dose increase, or that you are managing with escalating doses of laxatives, does. Your prescriber may be able to adjust the pace of dose escalation, or suggest a different approach, but only if they know about it. Reporting accurately matters, which is also why the MHRA's Yellow Card scheme exists for side effects that feel more significant than expected.

For anyone exploring treatment options or wanting to discuss how side effects are managed from the start, our prescribers cover all of this as part of the consultation process. Check your eligibility and see how the clinical conversation works before you commit to anything. You can also read more about Mounjaro as a treatment or look at how other side effects are approached at nume, including the hair loss that some people notice during Mounjaro treatment and how it is managed.